Literature DB >> 20530792

Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods.

Jessica A Reese1, Xiaoning Li, Manfred Hauben, Richard H Aster, Daniel W Bougie, Brian R Curtis, James N George, Sara K Vesely.   

Abstract

Drug-induced immune thrombocytopenia (DITP) is often suspected in patients with acute thrombocytopenia unexplained by other causes, but documenting that a drug is the cause of thrombocytopenia can be challenging. To provide a resource for diagnosis of DITP and for drug safety surveillance, we analyzed 3 distinct methods for identifying drugs that may cause thrombocytopenia. (1) Published case reports of DITP have described 253 drugs suspected of causing thrombocytopenia; using defined clinical criteria, 87 (34%) were identified with evidence that the drug caused thrombocytopenia. (2) Serum samples from patients with suspected DITP were tested for 202 drugs; drug-dependent, platelet-reactive antibodies were identified for 67 drugs (33%). (3) The Food and Drug Administration's Adverse Event Reporting System database was searched for drugs associated with thrombocytopenia by use of data mining algorithms; 1444 drugs had at least 1 report associated with thrombocytopenia, and 573 (40%) drugs demonstrated a statistically distinctive reporting association with thrombocytopenia. Among 1468 drugs suspected of causing thrombocytopenia, 102 were evaluated by all 3 methods, and 23 of these 102 drugs had evidence for an association with thrombocytopenia by all 3 methods. Multiple methods, each with a distinct perspective, can contribute to the identification of drugs that can cause thrombocytopenia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20530792      PMCID: PMC2951857          DOI: 10.1182/blood-2010-03-276691

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

Review 1.  Using MedDRA: implications for risk management.

Authors:  Elliot G Brown
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

2.  Conclusiveness of rechallenge in the interpretation of adverse drug reactions.

Authors:  M Girard
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

3.  Thrombocytopenia. I. Incidence and aetiology.

Authors:  L E Böttiger; B Westerholm
Journal:  Acta Med Scand       Date:  1972-06

4.  Drug-induced blood disorders.

Authors:  D A Danielson; S W Douglas; P Herzog; H Jick; J B Porter
Journal:  JAMA       Date:  1984-12-21       Impact factor: 56.272

5.  Platelet endothelial cell adhesion molecule-1 (PECAM-1) is a target glycoprotein in drug-induced thrombocytopenia.

Authors:  H Kroll; Q H Sun; S Santoso
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

6.  Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.

Authors:  Daniel W Bougie; Peter R Wilker; Elizabeth D Wuitschick; Brian R Curtis; Mohammad Malik; Stewart Levine; Richard N Lind; Jaime Pereira; Richard H Aster
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

7.  Acute thrombocytopenic purpura in relation to the use of drugs.

Authors:  D W Kaufman; J P Kelly; C B Johannes; A Sandler; D Harmon; P D Stolley; S Shapiro
Journal:  Blood       Date:  1993-11-01       Impact factor: 22.113

8.  Glycoprotein V: the predominant target antigen in gold-induced autoimmune thrombocytopenia.

Authors:  Stephen F Garner; Kate Campbell; Paul Metcalfe; Jane Keidan; Elly Huiskes; Jing-Fei Dong; José A López; Willem H Ouwehand
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

9.  Thrombocytopenia. II. Drug-induced thrombocytopenia.

Authors:  L E Böttiger; B Westerholm
Journal:  Acta Med Scand       Date:  1972-06

Review 10.  Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients.

Authors:  Annette J Neylon; Peter W G Saunders; Martin R Howard; Stephen J Proctor; Penelope R A Taylor
Journal:  Br J Haematol       Date:  2003-09       Impact factor: 6.998

View more
  33 in total

Review 1.  Drug-induced thrombocytopenia: an updated systematic review, 2012.

Authors:  Zayd L Al-Nouri; James N George
Journal:  Drug Saf       Date:  2012-08-01       Impact factor: 5.606

2.  Expanding the binding model of DITP.

Authors:  Renhao Li
Journal:  Blood       Date:  2015-10-29       Impact factor: 22.113

3.  Acute thrombocytopenia in patients treated with amiodarone is caused by antibodies specific for platelet membrane glycoproteins.

Authors:  Mervyn A Sahud; Michael Caulfield; Nigel Clarke; Robert Koch; Daniel Bougie; Richard Aster
Journal:  Br J Haematol       Date:  2013-08-19       Impact factor: 6.998

4.  Drug-induced thrombocytopenia: an updated systematic review, 2010.

Authors:  Long Nguyen; Jessica Reese; James N George
Journal:  Drug Saf       Date:  2011-05-01       Impact factor: 5.606

5.  Drug-induced thrombotic microangiopathy: Experience of the Oklahoma Registry and the BloodCenter of Wisconsin.

Authors:  Jessica A Reese; Daniel W Bougie; Brian R Curtis; Deirdra R Terrell; Sara K Vesely; Richard H Aster; James N George
Journal:  Am J Hematol       Date:  2015-02-25       Impact factor: 10.047

6.  Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis.

Authors:  Santiago Vilar; Rave Harpaz; Herbert S Chase; Stefano Costanzi; Raul Rabadan; Carol Friedman
Journal:  J Am Med Inform Assoc       Date:  2011-09-21       Impact factor: 4.497

7.  Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies.

Authors:  Brian R Curtis; Yen-Michael S Hsu; Nikolai Podoltsev; Jill Lacy; Susanna Curtis; Michael S Samuel; Kristin Zutavern; Robert A DeSimone; Daniel W Bougie; Richard H Aster
Journal:  Blood       Date:  2018-02-12       Impact factor: 22.113

8.  Drug-induced immune thrombocytopaenia: results from the Berlin Case-Control Surveillance Study.

Authors:  Edeltraut Garbe; Frank Andersohn; Elisabeth Bronder; Abdulgabar Salama; Andreas Klimpel; Michael Thomae; Hubert Schrezenmeier; Martin Hildebrandt; Ernst Späth-Schwalbe; Andreas Grüneisen; Oliver Meyer; Hanife Kurtal
Journal:  Eur J Clin Pharmacol       Date:  2011-12-21       Impact factor: 2.953

9.  Cytopenias among ART-naive patients with advanced HIV disease on enrolment to care and treatment services at a tertiary hospital in Tanzania: A cross-sectional study.

Authors:  Daniel W Gunda; Kahamba G Godfrey; Semvua B Kilonzo; Bonaventura C Mpondo
Journal:  Malawi Med J       Date:  2017-03       Impact factor: 0.875

Review 10.  Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.

Authors:  Brian A Baldo; Nghia H Pham
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.